May 2018 (Supplement)

Feature

From the Field

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

06/08/2018

Belinda R Avalos, MD

Jonathan Gerber, MD

Saad Z Usmani, MD, FACP

Michael R Grunwald, MD

Nilanjan Ghosh, MD, PhD

Manisha Bhutani, MD, PhD

Jigar Trivedi, MS, PharmD, BCOP

Dragos Plesca, PharmD, PhD, BCOP

Tammy Cogdill, MSN, ANP-BC, OCN

Zainab Shahi

To read the full article, click here.

To...

06/08/2018

Journal of Clinical Pathways

Perspectives

The Evolution of Care for Acute Myeloid Leukemia and the Challenges of Defining Value

05/21/2018

William J Cardarelli, PharmD

Abstract: Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Distinct subtypes of AML have been defined based on morphology, immunophenotyping, and molecular genetics. AML usually progresses...

...

05/21/2018

Journal of Clinical Pathways

Department

How Novel Agents Are Likely to Be Incorporated Into Clinical Pathways for Acute Myeloid Leukemia

05/21/2018

JCP Editors

Last year, the Food and Drug Administration (FDA) approved a total of 46 drugs, tying a record set for approvals in 2015. Cancer medications accounted for the majority of these approvals, with 16 oncology and 11...

Last...

05/21/2018

Journal of Clinical Pathways

Department

Research in Review

Acute Myeloid Leukemia Research Highlights

05/21/2018

JCP Editors

Clearance of Somatic Mutations and the Effect on Risk of Relapse in AML Clearance of somatic mutation at complete remission is associated with significantly better survival in patients with acute myeloid...

...

05/21/2018

Journal of Clinical Pathways

Column

Editor's Page

Implications of the Changing Landscape in Acute Myeloid Leukemia for Clinical Pathways

05/21/2018

Winston Wong, PharmD, Editor-in-Chief

Acute myelogenous leukemia (AML) is a rapid progressing malignancy of the myeloid progenitor cells, characterized by an uncontrolled proliferation of primitive blast cells replacing normal bone marrow cells. It is...

Acute...

05/21/2018

Journal of Clinical Pathways

Current Issue

April 2024

Volume 10

Issue 2

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

Biliary Tract Cancers (BTCs) Unveiled: Expert Perspectives on Unique Challenges and Management Considerations

11/20/2023

In this supplement, learn about the complexities of biliary tract cancer (BTC) with insights from a distinguished expert panel. The supplement examines the patient journey to diagnosis and treatment of BTCs, evaluates the impact of the...

In this supplement, learn about...

11/20/2023

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Twitter

Editorial Correspondence

May 2018 (Supplement)

Feature

Department

Column

Current Issue

Special Reports

Subscribe

Twitter

Volume 4

Specialties

Events

Year Round Education

HMP Global Products